Heterogeneous phenotype of human glioblastoma: In vitro study |
| |
Authors: | Tetyana Denysenko Luisa Gennero Carola Juenemann Isabella Morra Paolo Masperi Vincenzo Ceroni Antonella Pragliola Antonio Ponzetto Antonio Melcarne |
| |
Affiliation: | 1. Neurosurgery, ASO CTO, OIRM S. Anna, Turin, Italy;2. Consorzio Carso Laboratories, Valenzano, Bari, Italy;3. Pathology, ASO CTO, OIRM S. Anna, Turin, Italy;4. CoreLab, Laboratorio di Unico Area Vasta Romagna, Pievesestina di Cesena (FC), Forlì‐Cesena, Italy;5. Department of Internal Medicine, University of Turin, Turin, Italy |
| |
Abstract: | Glioblastomas (GBMs) are the most lethal primary brain tumours. Increasing evidence shows that brain tumours contain the population of stem cells, so‐called cancer stem cells (CSCs). Stem cell marker CD133 was reported to identify CSC population in GBM. Further studies have indicated that CD133 negative cells exhibiting similar properties and are able to initiate the tumour, self‐renew and undergo multilineage differentiation. GBM is a highly heterogeneous tumour and may contain different stem cell populations with different functional properties. We characterized five GBM cell lines, established from surgical samples, according to the marker expression, proliferation and differentiation potential. CD133 positive cell lines showed increased proliferation rate in neurosphere condition and marked differentiation potential towards neuronal lineages. Whereas two cell lines low‐expressing CD133 marker showed mesenchymal properties in vitro, that is high proliferation rate in serum condition and differentiation in mesenchymal cell types. Further, we compared therapy resistance capacity of GBM cell lines treated with hydroxyurea. Our results suggest that CSC concept is more complex than it was believed before, and CD133 could not define entire stem cell population within GBM. At least two different subtypes of GBM CSCs exist, which may have different biological characteristics and imply different therapeutic strategies. Copyright © 2013 John Wiley & Sons, Ltd. |
| |
Keywords: | glioblastoma cancer stem cells CD133 hydroxyurea glioblastoma subtypes |
|
|